IN2014CN02448A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02448A
IN2014CN02448A IN2448CHN2014A IN2014CN02448A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A IN 2448CHN2014 A IN2448CHN2014 A IN 2448CHN2014A IN 2014CN02448 A IN2014CN02448 A IN 2014CN02448A
Authority
IN
India
Prior art keywords
glucagon peptides
obesity
treatment
present
peptides
Prior art date
Application number
Other languages
English (en)
Inventor
Jesper F Lau
Thomas Kruse
Henning Thøgersen
Ulrich Sensfuss
Peter Kresten Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IN2014CN02448A publication Critical patent/IN2014CN02448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IN2448CHN2014 2011-09-23 2012-09-21 IN2014CN02448A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11182476 2011-09-23
US201161539148P 2011-09-26 2011-09-26
PCT/EP2012/068649 WO2013041678A1 (en) 2011-09-23 2012-09-21 Novel glucagon analogues

Publications (1)

Publication Number Publication Date
IN2014CN02448A true IN2014CN02448A (pt) 2015-06-19

Family

ID=47911932

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2448CHN2014 IN2014CN02448A (pt) 2011-09-23 2012-09-21

Country Status (17)

Country Link
US (4) US8541368B2 (pt)
EP (1) EP2758426B1 (pt)
JP (2) JP6352806B2 (pt)
KR (1) KR20140070612A (pt)
CN (1) CN104093735B (pt)
AR (1) AR088161A1 (pt)
AU (1) AU2012311484B2 (pt)
BR (1) BR112014006684A2 (pt)
CA (1) CA2849673A1 (pt)
IL (1) IL231199A0 (pt)
IN (1) IN2014CN02448A (pt)
MX (1) MX354705B (pt)
MY (1) MY167234A (pt)
RU (2) RU2017101333A (pt)
TW (1) TWI596110B (pt)
WO (1) WO2013041678A1 (pt)
ZA (1) ZA201401603B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
NZ704043A (en) * 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
HUE045573T2 (hu) * 2013-04-18 2020-01-28 Novo Nordisk As Stabil, hosszú hatóidejû GLP-1/glükagon receptor ko-agonisták, gyógyászati alkalmazásra
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EP3065767B1 (en) 2013-11-06 2020-12-30 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CN106029088A (zh) * 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106536547A (zh) * 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104926934B (zh) * 2014-09-23 2016-11-09 蒋先兴 胃泌酸调节素类似物
ES2805326T3 (es) * 2014-10-10 2021-02-11 Novo Nordisk As Coagonistas estables del receptor de GLP-1/glucagón basados en GLP-1
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10308701B2 (en) 2015-07-22 2019-06-04 Purdue Research Foundation Modified glucagon molecules
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
LT3402811T (lt) * 2016-01-13 2022-06-10 Novo Nordisk A/S Egf(a) analogai su riebalų rūgščių pakaitais
KR20200028399A (ko) * 2017-07-13 2020-03-16 후지세유 그룹 혼샤 가부시키가이샤 펩타이드
TW201918494A (zh) 2017-07-19 2019-05-16 丹麥商諾佛 儂迪克股份有限公司 雙功能性化合物
CN111164128A (zh) 2017-09-29 2020-05-15 韩美药品株式会社 包含作为接头的非肽基聚合物偶联的脂肪酸衍生物化合物的蛋白复合物及其制备方法
JP7212171B2 (ja) 2019-02-05 2023-01-24 イーライ リリー アンド カンパニー グルカゴン類似体アゴニストおよびその使用方法
WO2021127460A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
TW202227474A (zh) * 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ－１及澱粉素受體之共促效劑
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
CN113759048B (zh) * 2021-10-14 2022-06-21 成都普康唯新生物科技有限公司 一种十八烷二酸单叔丁酯检验方法

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
IL93173A0 (en) 1989-02-01 1990-11-05 Shionogi & Co Production of glucagon
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE69626660T2 (de) 1995-09-08 2003-08-21 Novo Nordisk As 2-alkylpyrrolidine
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
RU2200161C2 (ru) 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение
DE69727837T2 (de) 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU6966498A (en) 1997-12-02 1998-10-30 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
JP2002527502A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの調製及び使用
WO2000023417A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000023415A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
HUP0104646A3 (en) 1998-12-18 2004-05-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
BR0010683A (pt) 1999-04-16 2003-07-01 Reddy Research Foundation Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
EP1171414A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
EP1171431A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
EP1591453A1 (en) 1999-05-17 2005-11-02 ConjuChem Inc. Modified peptides yy and conjugates thereof
ATE346093T1 (de) * 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
ATE297907T1 (de) 2000-07-20 2005-07-15 Hoffmann La Roche Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
ES2291613T3 (es) 2002-01-16 2008-03-01 Biocompatibles Uk Limited Conjugados de polimeros.
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1503283A1 (en) 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
CA2531988C (en) * 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
JP4566194B2 (ja) 2003-08-12 2010-10-20 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
EP3138855A1 (en) 2005-02-23 2017-03-08 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
US20090062192A1 (en) 2005-03-18 2009-03-05 Novo Nordisk A/S Dimeric Peptide Agonists of the Glp-1 Receptor
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
JP2008543816A (ja) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
KR20080016674A (ko) 2005-06-15 2008-02-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 트랜스글루타미나제 매개 성장 호르몬 컨쥬게이션
KR20080031414A (ko) 2005-07-18 2008-04-08 노보 노르디스크 에이/에스 비만치료에 사용하기 위한 신규 펩티드
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
CA2638779C (en) 2006-01-31 2017-01-03 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
US8669228B2 (en) * 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP2010531135A (ja) 2007-06-04 2010-09-24 ノボ ノルディスク アクティーゼルスカブ Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
US8460909B2 (en) 2007-06-15 2013-06-11 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100210553A1 (en) 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
CN102088989B (zh) * 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PE20100255A1 (es) 2008-06-17 2010-04-25 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102171244B (zh) 2008-08-07 2015-05-13 益普生制药股份有限公司 糖依赖性胰岛素释放肽的类似物
SI2349342T1 (sl) 2008-10-17 2018-10-30 Baxalta GmbH Modificirani krvni faktorji, ki obsegajo nizko stopnjo v vodi topnega polimera
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
UA104605C2 (uk) * 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
WO2010102886A1 (en) 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
AU2010260058B2 (en) 2009-06-16 2015-09-24 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2552951A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
WO2011160633A1 (en) * 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
NZ611878A (en) 2010-12-22 2015-02-27 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EP2665487A1 (en) 2011-01-20 2013-11-27 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
AU2012234276A1 (en) * 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012158964A2 (en) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals for osteoporosis
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
EP3434687B1 (en) 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20140221283A1 (en) 2011-06-22 2014-08-07 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения

Also Published As

Publication number Publication date
CA2849673A1 (en) 2013-03-28
BR112014006684A2 (pt) 2017-03-28
AU2012311484B2 (en) 2017-04-13
RU2610175C2 (ru) 2017-02-08
AR088161A1 (es) 2014-05-14
AU2012311484A1 (en) 2014-03-06
RU2017101333A (ru) 2018-12-19
JP2018021081A (ja) 2018-02-08
RU2014114434A (ru) 2015-10-27
MX354705B (es) 2018-03-16
EP2758426B1 (en) 2019-08-07
CN104093735B (zh) 2018-07-06
JP2014527975A (ja) 2014-10-23
JP6352806B2 (ja) 2018-07-04
ZA201401603B (en) 2015-02-25
US9486505B2 (en) 2016-11-08
EP2758426A1 (en) 2014-07-30
TWI596110B (zh) 2017-08-21
US20160347812A1 (en) 2016-12-01
IL231199A0 (en) 2014-04-30
WO2013041678A1 (en) 2013-03-28
US20150182594A1 (en) 2015-07-02
MX2014003312A (es) 2014-04-25
US9486506B2 (en) 2016-11-08
US20130288958A1 (en) 2013-10-31
MY167234A (en) 2018-08-14
KR20140070612A (ko) 2014-06-10
US20130079278A1 (en) 2013-03-28
CN104093735A (zh) 2014-10-08
TW201329102A (zh) 2013-07-16
US8541368B2 (en) 2013-09-24

Similar Documents

Publication Publication Date Title
IN2014CN02448A (pt)
MX2013011175A (es) Analogos de glucagon novedosos.
MX336412B (es) Nuevos analogos de glucagon.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2015008114A (es) Derivados de exendina-4.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
IL239488B (en) A gpc3-targeted medicinal agent administered to a patient who responds to treatment with a gpc3-targeted medicinal agent
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
UA112981C2 (uk) Варіант людського gdnf
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
GB201304462D0 (en) Therapeutic vaccine for treatment of type 2 diabetes and impaired glucose tolerance
UA53217U (en) Mask for therapy and general health improvement
UA53455U (ru) Способ лечения некоторых дерматозов
UA78287U (ru) Способ медицинской реабилитации больных ишемической болезнью сердца на фоне метаболического синдрома
TH0901003547A (th) การรักษาสำหรับโรคเบาหวานในคนไข้ที่ไม่เหมาะสำหรับการรักษาด้วยเมทฟอร์มิน